[Forbes.com] The Sovaldi Tax: Gilead Can’t Justify The Price It’s Asking For Hepatitis C Therapy
A cure for hepatitis C is within reach for 170 million people around the world… Read More
A cure for hepatitis C is within reach for 170 million people around the world… Read More
Eyeing a $168-million annual price tag for two costly new hepatitis C drugs,… Read More
“The people who pay for drugs aren’t fully buying those arguments —… Read More
“The outcry continues over the $1,000-a-pill hepatitis C drug made by… Read More
“A broad coalition of health care groups is trying to compel the… Read More
“More than 80 organizations are launching the Campaign for Sustainable Rx… Read More
By Meg Tirrell May 22, 2014 The mounting scrutiny of prescription drug… Read More
By Michael Smith May 22, 2014 The evidence base for one of the star… Read More
By Anthony Brino May 21, 2014 The breakthrough hepatitis drug Sovaldi… Read More
By Brett Norman May 21, 2014 The astronomical price of a new “miracle”… Read More
By John Wilkerson May 21, 2014 Spurred by the prospect of Sovaldi’s… Read More
By Bill Berkrot May 21, 2014 The leading U.S. health insurance trade… Read More